Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 9:83:103201.
doi: 10.1016/j.eclinm.2025.103201. eCollection 2025 May.

The effects of exercise on secondary prevention and health-related quality of life in people with existing vascular disease: systematic review and meta-analysis of randomised controlled trials

Affiliations

The effects of exercise on secondary prevention and health-related quality of life in people with existing vascular disease: systematic review and meta-analysis of randomised controlled trials

Cathryn Broderick et al. EClinicalMedicine. .

Abstract

Background: Polyvascular disease (atherosclerosis across two or more vascular beds) is becoming increasingly common, yet systematic reviews of interventions such as exercise are traditionally targeted at people with a single disease. We aimed to determine the effect of exercise in the secondary prevention of major adverse cardiovascular events and health-related quality of life (HRQoL) in people with an existing vascular disease and to assess the impact of polyvascular disease.

Methods: For this systematic review and meta-analysis, we searched databases (Cochrane Register of Studies Online, MEDLINE, Embase Ovid, CINAHL EBSCO, WHO-ICTRP and ClinicalTrials.gov) in January 2025 for randomised controlled trials (RCTs) of exercise in people with coronary artery disease, heart failure, stroke (including transient ischaemic attack (TIA)) and peripheral arterial disease (PAD). We excluded studies where exercise was delivered for <6 weeks. Two reviewers independently assessed articles for eligibility and extracted data. Disagreements were resolved through discussion. Critical outcomes were mortality (all-cause and cardiovascular-specific), vascular events (myocardial infarction, stroke, amputation, acute limb ischaemia (ALI)), vascular hospitalisations, and HRQoL (EQ-5D and SF-36). We extracted data at end of intervention, medium term (6-30 months follow-up), and long term (>30 months follow-up). We performed random-effects meta-analyses. Risk of bias was assessed using Cochrane's Risk of Bias 1 tool. The certainty of the evidence was assessed using GRADE. PROSPERO registration: CRD42024517019.

Findings: We included 280 RCTs involving 23,419 participants. 114 (40·71%) studies did not report whether their populations had more than one vascular disease. Exercise may result in little to no difference in all-cause mortality compared to no exercise at end of intervention (risk ratio (RR) 0·92, 95% confidence interval (CI) 0·80-1·07; P = 0·30; 143 studies, 12,811 participants; low-certainty evidence). Similar effects were found at medium and long term. Exercise may result in little to no difference in cardiovascular mortality compared to no exercise at end of intervention (RR 0·92, 95% CI 0·75-1·12; P = 0·41; 77 studies, 7319 participants; low-certainty evidence). A similar effect was found at medium term. At long term there may be a difference favouring exercise on cardiovascular mortality (RR 0·81, 95% CI 0·64-1·01; P = 0·06; 10 studies, 3935 participants). Exercise probably reduces vascular hospitalisations compared to no exercise at end of intervention (RR 0·73, 95% CI 0·56-0·95; P = 0·02; 64 studies, 7101 participants; moderate-certainty evidence) and medium term (RR 0·83, 95% CI 0·70-0·99; P = 0·04; 49 studies, 7514 participants; low-certainty evidence), with little or no difference at long term. Exercise probably increases HRQoL as assessed by EQ-5D compared to no exercise at end of intervention (mean difference (MD), 6·20, 95% CI 2·21-10·20; P = 0·002; 8 studies, 805 participants; moderate-certainty evidence), with little or no difference at medium term (MD 2·23, 95% CI -3·19 to 7·66; P = 0·42; 7 studies, 707 participants; moderate-certainty evidence) and long term (MD 6·00, 95% CI -2·05 to 14·05; P = 0·14; 1 study, 73 participants). Exercise probably increases HRQoL as assessed by SF-36 compared to no exercise at end of intervention (MD 6·83, 95% CI 5·22-8·44; P < 0·0001; 50 studies, 3231 participants; moderate-certainty evidence) and medium term (MD 6·44, 95% CI 3·71-9·18; P < 0·0001; 15 studies, 1522 participants; moderate-certainty evidence). No studies reported SF-36 at long term. Data on vascular events were mixed and of low certainty. Evidence was limited, and therefore uncertain, for amputation and ALI. Limiting issues were poor descriptions of exercise, and poor, inconsistently reported study inclusion and exclusion criteria, therefore limiting our ability to categorise included populations as polyvascular/single.

Interpretation: We believe this systematic review and meta-analysis to be the first to combine RCTs with vascular diseases and examine the effects of exercise in people with single conditions and polyvascular disease. We found consistent evidence that exercise improves HRQoL and reduces hospitalisations across vascular disease but does not appear to impact mortality. However, the vast majority of trials were designed to target people with a single vascular condition and did not report the presence of additional vascular diseases. Therefore, it was not possible to formally assess the impact of the addition of polyvascular disease on exercise outcomes or determine the applicability of our findings to a population with polyvascular disease. More trials are needed that include participants with polyvascular conditions to strengthen the evidence on safety of this intervention, in order to inform clinical guidelines.

Funding: This study was funded by the NIHR Evidence Synthesis Programme (NIHR162044).

Keywords: Exercise; Meta-analysis; Polyvascular; Secondary prevention; Systematic review; Vascular disease.

PubMed Disclaimer

Conflict of interest statement

Cathryn Broderick: none known. This project was funded by the NIHR Evidence Synthesis Programme (programme grant: NIHR153425, project number NIHR162044). Payment to institution. Marlene Stewart: none known. NIHR Evidence Synthesis Programme (programme grant: NIHR153425, project number NIHR162044). Payment to institution. Katie Thomson: none known. Ceri Sellers: none known. Candida Fenton: none known. Julie Cowie: none known. Wei Xu: none known. Christa St Jean: none known. NIHR Evidence Synthesis Programme (programme grant: NIHR153425, project number NIHR162044). Payment to institution. Keira Charteris: none known. Madhurima Nundy: none known. Vaishali Vardhan: none known. Prerna Krishan: none known. Jolie Pistol: volunteer member of UNCOVER. Leonor Rodríguez: none known. Alex Todhunter-Brown: NIHR Evidence Synthesis Programme funds NESSIE (NIHR Evidence Synthesis Scotland Initiative). I am co–lead investigator on NESSIE. Funding to institutions for NESSIE funds researcher time to conduct the work presented in this manuscript. Co–Lead Cochrane Heart, Stroke & Circulation Thematic Group. This group supports the planning, conduct and dissemination of Cochrane systematic reviews. This is an unpaid role, with no financial involvement in any Cochrane activities or reviews. Frederike van Wijck: receives royalties for publication of Mead G & van Wijck F (Eds). Exercise and fitness training after stroke: a handbook for evidence-based practice (2013). Sheila Cameron: none known. Catriona Keerie: none known. Rod S Taylor: none known. Gerry Stansby: none known. Gillian Mead: Around £20 a year for a book published by Elsevier about exercise training after stroke.

Figures

Fig. 1
Fig. 1
PRSIMA flow diagram.
Fig. 2
Fig. 2
Vascular hospitalisations at end of intervention.
Fig. 3
Fig. 3
Vascular hospitalisations at medium term.
Fig. 4
Fig. 4
HRQoL: SF-36 at end of intervention.
Fig. 5
Fig. 5
HRQoL: SF-36 at medium term.

References

    1. Vaduganathan M., Mensah G.A., Turco J.V., Fuster V., Roth G.A. The global burden of cardiovascular diseases and risk: a compass for future health. J Am Coll Cardiol. 2022;80(25):2361–2371. - PubMed
    1. WHO Cardiovascular diseases (CVDs) 2021. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases... Available from:
    1. Virani S.S., Alonso A., Benjamin E.J., et al. Heart disease and stroke statistics - 2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139–e596. - PubMed
    1. Bhatt D.L., Eagle K.A., Ohman E.M., et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304(12):1350–1357. - PubMed
    1. Gutierrez J.A., Aday A.W., Patel M.R., Jones W.S. Polyvascular disease: reappraisal of the current clinical landscape. Circ Cardiovasc Interv. 2019;12(12) - PMC - PubMed

LinkOut - more resources